The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
The prospectus usually comes a good few weeks before trading actually commences so should see a prospectus this month I’m hoping
Prospectus should be out this month then presumably?
Bank holiday in the states tomorrow, presuming that wouldn’t impact the company’s thinking with regards to putting them off though, the only thing is in theory there would be more news coverage stateside if the markets were open there but I’m probably just overthinking that element no doubt!
I’m sure all holders will quickly forget a few days or even a weeks delay in the release of the RNS if it contain news regarding a licensing deal or a sale of part of the business or even the whole business. The market doesn’t seem to view the RNS not being out yet as an issue hence the sp rising over 8% this week.
Does sound like Avacta would be a strong candidate for sure.
What new info was contained in todays update has increased your positivity? Thanks
Correction: if the sp did in fact finish 134.10 then it’s a 8.47% increase this week.
Finish 132.63. 7.28% increase this week. Not bad at all.
The market doesn’t seem to be falling for the delay or uncertainty narrative this week though as sp is
+ 7.10!
We still have no idea of the terms for SH though until
the prospectus is released
Trading by the end of next month? I didn’t see a February date mentioned in this interim statement?
I agree with that part of your post, shouldn’t be any issue with you posting your view even on here even if many disagree with that view, as long as they are civil and respectful in their responses of course.
I believe if news is significant and revolutionary enough then “macro environment” or not, the MC will grow and rerate accordingly irrespective of any peripheral going on as some news is considered to be so exceptional that nothing gets in its way.
“There have been numerous NASDAQ listed biotechs that have released fantastic P2 data that included comprehensive efficacy data and the spike didn't hold.”
Were any of those company’s working on ways to revolutionise and target tumours like Avacta are though? If not then you can’t really compare them can you I don’t think.
I think the more positive posters are just referencing the positive indicators from all publicly available material, the deramp crew members and trolls seem to have very little to work with apart from conflating the previous LFT situation and somehow trying to conflate that outcome with what could happen with this trial which is obviously silly as they are very much different in every aspect!
Oh, not significant then in your view? Or are you just being contrarian for the sake of it?
Also in that vein, would it be reasonable to expect an additional RNS prior to the science day presentation just to make sure that don’t disclose anything price sensitive? Can investors watch it live? Or is it behind closed doors? Thanks
Guessing with all this info appearing in public the company will need to be releasing the RNS otherwise this info could be classed as price sensitive.
Looking for much much more than 10%! I could have taken a profit yesterday but didn’t, saw that profit disappear today and am not down overall slightly but not concerned.
Sorry I’m not familiar with all of the intricacies of pharmaceutical science like you yourself presumably are, fortunately I’m still allowed to invest and post my views, even if the bullies don't like it.